Cell and secretome-based therapies: Translating science into clinical practice

This course will run from 23 April - 24 April 2020 in Pavia, Italy THURSDAY 23 APRIL 08:15 Registration 08:45 Welcome 09:00 Regulatory affairs and GMP production Presentations: Regulatory affairs - update GMP production of ATMPs for clinical use G Astori, Vicenza GMP production of biologicals for clinical use A Peterbauer, Linz A model of … Continue reading "Cell and secretome-based therapies: Translating science into clinical practice"

This course will run from 23 April – 24 April 2020 in Pavia, Italy

THURSDAY 23 APRIL
08:15 Registration
08:45 Welcome
09:00 Regulatory affairs and GMP production
Presentations:
Regulatory affairs – update
GMP production of ATMPs for clinical use G Astori, Vicenza
GMP production of biologicals for clinical use A Peterbauer, Linz
A model of a publicly funded institution supporting the development of ATMPs N Cuende, Seville
11:00 Break
11:30 Cell therapy: where do we stand?
Presentations:
What can be truly regenerated?
From cells to cell products
13:00 Lunch
14:00 Secretome and extracelluar vesicles
Presentations:
MSC conditioned media for tissue repair M Gnecchi, Pavia
Biological properties of extracellular vesicles and their physiological functions B Giebel, Essen
Extracellular vesicles for tissue repair – Systems biology approaches to investigating the therapeutic potential of extracellular vesicles
Stressed PBMCS secretome – content/function and therapeutic indications H J Ankersmit, Vienna
16:00 Coffee Break
16:30 Young Investigator Session
Presentations:
How to build a successful career in cell therapy M Dominici, Modena
Abstract presentations
17:30 Close
FRIDAY 24 APRIL

 

08:30 ATMPs versus biologicals for tissue repair
Presentations:
Safety testing of biologics and advanced therapies
How Holoclar became the first stem cell product approved in Europe G Pellegrini, Modena
MSC secretome – relevance in neurological indications A Salgado, Braga
Successful translation of cell secretome in diabetic foot ulcer clinical trial G Gouya, Vienna
10:30 Coffee Break
11:00 Clinical and translation studies testing cell-based therapies for cardiovascular diseases
Presentations:
Cell therapy trials for heart regeneration – lessons learned and future directions P Menasche, Paris
BMC and the BAMI trial S Janssens, Leuven
Discovery of secretome-derived molecules for heart repair K Wollert, Hanover
TBA
13:00 Lunch
14:00 Hot topics
Presentations:
How the CRISP technology will change medicine B Levine, Philadelphia
iPSC in 2020 J S Hulot, Paris
miRNA levels in a model of osteoporosis and therapy
microRNA and heart repair: what’s new?
15:30 Coffee Break
16:00 Tissue engineering: where do we stand in 2020?
Presentations:
Tissue engineering of the future I Martin, Basel
Decellularization for tissue regeneration
Engineered valves J Kluin, Amsterdam
Tissue and organ 3D bioprinting
17:30 Winners of best abstracts and best posters and closing remarks
18:00 Close

COURSE INFORMATION

Date/Duration
23 April- 24 April 2020 (2 day course)

Location
Almo Collegio Borromeo
Pavia, Italy

Course Directors
M Gnecchi, Pavia; HJ Ankersmit, Vienna

Course Format
The 2 day programme will include keynote presentations, a young investigator session and poster presentation.

Course Fee
Delegates: €200 inclusive of VAT
Industry: €275 inclusive of VAT
Students: €50 inclusive of VAT

Fee includes lunch and refreshments on 23 and 24 April.

Target Audience
Cardio-thoracic surgeons and Cardiologists interested in translational science, professionals involved with regulatory affairs in applied research and the translation of ATMP and secretome based regenerative products to the bedside. Basic Scientists, Biologists, Biotechnologists, Residents and Fellows of all surgical and clinical specialities, particularly the youngest.

Learning Objectives
Participants will learn the latest advancements in the field of cell and molecular therapy for tissue repair. The use of specific cell populations (ATMPs) and cell derived molecules (such as proteins and microvescicles) for the treatment of different diseases will be discussed. Also, an update on cell and tissue engineering developments will be presented.

A further objective of this symposium is the description of the complex interplay between regulatory affairs and basic/translational science in order to transfer scientific research to the patients.

ABSTRACTS

Click here to view the call for abstracts.

Faculty

  • Massimiliano Gnecchi
  • Hendrik Jan Ankersmit
  • Bernd Giebel
  • Jolanda Kluin
  • Kai Wollert
  • Philippe Menasche
  • Graziella Pellegrini
  • Natividad Cuende
  • Antonio Salgado
  • Ivan Martin
  • Giuseppe Astori
  • Ghazaleh Gouya Lechner
  • Anja Peterbauer-Scherb